Iterum Therapeutics plc (ITRMF) Change in Accured Expenses (2017 - 2025)

Iterum Therapeutics has reported Change in Accured Expenses for 9 years, with the latest figure at $1.3 million in Q3 2025.

• On a quarterly basis, Change in Accured Expenses rose 9.1% year-over-year to $1.3 million in Q3 2025; TTM through Sep 2025 was $1.8 million, a 132.42% increase from a year earlier, with the FY2024 full-year figure at -$5.1 million, down 246.46% from the prior year.
• Change in Accured Expenses was $1.3 million for Q3 2025 at Iterum Therapeutics, up from $1.1 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $4.0 million in Q3 2023, with the low at -$5.9 million in Q1 2024.
• Average Change in Accured Expenses over 5 years is $162842.1, with a median of $401000.0 recorded in 2024.
• The sharpest annual moves came in 2022 and 2024: Change in Accured Expenses jumped 690.91% in 2022, then slumped 689.04% in 2024.
• Over 5 years, Change in Accured Expenses stood at -$423000.0 in 2021, then surged by 243.74% to $608000.0 in 2022, then tumbled by 312.01% to -$1.3 million in 2023, then soared by 34.83% to -$840000.0 in 2024, then soared by 259.88% to $1.3 million in 2025.
• The last three Change in Accured Expenses figures came in at $1.3 million (Q3 2025), $1.1 million (Q2 2025), and $227000.0 (Q1 2025), per Business Quant data.